SILK ROAD MEDICAL INC (SILK)
US82710M1009 - Common Stock
Overall SILK gets a fundamental rating of 3 out of 10. We evaluated SILK against 188 industry peers in the Health Care Equipment & Supplies industry. SILK scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SILK is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SILK had negative earnings in the past year.
SILK had a negative operating cash flow in the past year.
In the past 5 years SILK always reported negative net income.
SILK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -20.96%, SILK perfoms like the industry average, outperforming 51.87% of the companies in the same industry.
Looking at the Return On Equity, with a value of -36.55%, SILK is in line with its industry, outperforming 54.01% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| ROIC | N/A |
ROA(3y)-24.4%
ROA(5y)-27.56%
ROE(3y)-44.44%
ROE(5y)-50.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SILK has a Gross Margin of 74.28%. This is amongst the best in the industry. SILK outperforms 85.03% of its industry peers.
In the last couple of years the Gross Margin of SILK has remained more or less at the same level.
SILK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.03%
GM growth 5Y0.93%
2. Health
2.1 Basic Checks
SILK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SILK has more shares outstanding
SILK has more shares outstanding than it did 5 years ago.
SILK has a worse debt/assets ratio than last year.
2.2 Solvency
SILK has an Altman-Z score of 4.49. This indicates that SILK is financially healthy and has little risk of bankruptcy at the moment.
SILK has a Altman-Z score of 4.49. This is in the better half of the industry: SILK outperforms 72.73% of its industry peers.
SILK has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SILK (0.49) is worse than 64.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.49 |
ROIC/WACCN/A
WACC8.47%
2.3 Liquidity
SILK has a Current Ratio of 7.63. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.63, SILK belongs to the top of the industry, outperforming 85.56% of the companies in the same industry.
SILK has a Quick Ratio of 6.69. This indicates that SILK is financially healthy and has no problem in meeting its short term obligations.
SILK has a better Quick ratio (6.69) than 83.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.63 | ||
| Quick Ratio | 6.69 |
3. Growth
3.1 Past
SILK shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.13%.
SILK shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.54%.
SILK shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.63% yearly.
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y38.63%
Sales Q2Q%13.12%
3.2 Future
The Earnings Per Share is expected to grow by 3.87% on average over the next years.
The Revenue is expected to grow by 13.50% on average over the next years. This is quite good.
EPS Next Y-3.77%
EPS Next 2Y3.37%
EPS Next 3Y3.9%
EPS Next 5Y3.87%
Revenue Next Year16.35%
Revenue Next 2Y13.73%
Revenue Next 3Y12.46%
Revenue Next 5Y13.5%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
SILK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SILK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.37%
EPS Next 3Y3.9%
5. Dividend
5.1 Amount
No dividends for SILK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SILK ROAD MEDICAL INC
NASDAQ:SILK (9/16/2024, 8:00:02 PM)
After market: 27.49 0 (0%)27.49
-0.01 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.12B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.96% | ||
| ROE | -36.55% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.28% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.63 | ||
| Quick Ratio | 6.69 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-2.13%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-3.77%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)17.54%
Revenue growth 3Y33.05%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y